Urothelial Carcinoma of the Prostate

Urology

Volumn 69, Issue 1 SUPPL., 2007, Pages 50-61

  Palou, Juan ^a   Baniel, Jack ^b   Klotz, Laurence ^c   Wood, David ^d   Cookson, Michael ^e   Lerner, Seth ^f   Horie, Shigeo ^g   Schoenberg, Mark ^h   Angulo, Javier ⁱ   Bassi, Pierfranco ^j  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b RABIN MEDICAL CENTER   (Israel)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF MICHIGAN   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g KYORIN UNIVERSITY   (Japan)

^h DEPARTMENT OF PATHOLOGY   (United States)

ⁱ HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^j UNIVERSITY OF PADOVA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; EPIRUBICIN;

ARTICLE; BCG VACCINATION; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER INCIDENCE; CANCER INVASION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARCINOMA IN SITU; CASE STUDY; CONSENSUS; CYSTECTOMY; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; DRUG PENETRATION; DRUG TREATMENT FAILURE; EVIDENCE BASED MEDICINE; FOLLOW UP; FROZEN SECTION; HISTOPATHOLOGY; HUMAN; MEDICAL LITERATURE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PELVIS LYMPHADENECTOMY; PEROPERATIVE CARE; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT RESPONSE; TUMOR BIOPSY; URETHRA CARCINOMA; URINARY TRACT CARCINOMA; WORLD HEALTH ORGANIZATION;

CARCINOMA, TRANSITIONAL CELL; DIAGNOSIS, DIFFERENTIAL; HUMANS; INCIDENCE; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; WORLD HEALTH;

EID: 33846586702     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.05.059     Document Type: Article

References (65)

1. Harmer M.H. International Union Against Cancer: TNM Classification of Malignant Tumours. 6th ed. (2002), International Union Against Cancer, Geneva, Switzerland
2. Wittekind C.H., Henson D.E., Hutter R.V.P., et al. TNM Supplement: A Commentary on Uniform Use. 2nd ed. (2001), John Wiley & Sons, Inc, New York
3. Abrams P, Grant A, Khoury S. Evidence-based medicine: overview of the main steps for developing and grading guideline recommendations. In Abrams P, Cardozo L, Khoury S, et al (Eds), Incontinence, Volume 1. Plymouth, United Kingdom, Health Publications Ltd., pp 10-11.
4. Ortega L.M., Whitmore F.R.J., and Murphy A.J. In situ carcinoma of the prostate with intra-epithelial extension into the urethra and bladder. Cancer 6 (1953) 898-923
5. Rikken C.H.M., Van Helsdingen P.J.R.O., and Kazzaz B.A. Are biopsies from the prostatic urethra useful in patients with superficial bladder carcinoma?. Br J Urol 59 (1987) 145-147
6. Solsona E., Iborra I., Ricós, et al. Recurrence of superficial bladder tumors in the prostatic urethra. Eur Urol 19 (1991) 89-92
7. Matzkin H., Soloway M.S., and Hardeman S. Transitional cell carcinoma of the prostate. J Urol 146 (1991) 1207-1212
8. Millan-Rodriguez F., Chechile-Toniolo G., Salvador-Bayarri J., et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 163 (2000) 73-78
9. Davis J.W., Sheth S.I., Doviak M.J., et al. Superficial bladder carcinoma treated with bacillus Calmette-Guérin: progression-free and disease specific survival with minimum 10-year followup. J Urol 167 pt 1 (2002) 494-500 discussion 501
10. Herr H.W., and Donat S.M. Prostatic tumor relapse in patients with superficial bladder tumors: 15 year outcome. J Urol 161 (1999) 1854-1857
11. Bassi P.F. BCG (bacillus Calmette-Guérin) therapy of high risk superficial bladder cancer. Surg Oncol 11 (2002) 77-83
12. Wood Jr. D.P., Montie J.E., Pontes J.E., et al. Transitional cell carcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. J Urol 141 (1989) 346-349
13. Revelo M.P., Cookson M.S., Chang S.S., et al. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for apical sparing surgery. J Urol 171 (2004) 646-651
14. Nixon R.G., Chang S.S., Lafleur B.J., et al. Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder. J Urol 167 (2002) 502-505
15. Esrig D., Freeman J.A., Elmajian D.A., et al. Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion. J Urol 156 (1996) 1071-1076
16. Hardeman S.W., and Soloway M.S. Transitional cell carcinoma of the prostate: diagnosis, staging and management. Word J Urol 6 (1988) 170-174
17. Schellhammer P.F., Bean M.A., and Whitmore W.F.J. Prostatic involvement by transitional cell carcinoma: pathogenesis, patterns and prognosis. J Urol 118 (1997) 399-403
18. Seemayer T.A., Knaack J., Thelmo W.L., et al. Further observations on carcinoma in situ of the urinary bladder: silent but extensive intraprostatic involvement. Cancer 36 (1975) 514-520
19. Orihuela E., Herr W.H., and Whitmore W.F. Conservative treatment of superficial transitional cell carcinoma of the prostatic urethra with intravesical BCG. Urology 34 (1989) 231-237
20. Thelmo W.L., Seemayer T.A., Madarnas P., et al. Carcinoma in situ of the bladder with associated prostatic involvement. J Urol 111 (1974) 491-494
21. Schellhammer P.F., Ladaga L.E., and Morarty R.P. Intravesical bacillus Calmette-Guérin for treatment of superficial transitional cell carcinoma of prostatic urethra in association with carcinoma of the bladder. J Urol 153 (1995) 53-56
22. Hillyard R.W., Ladaga L., and Schellhammer P.F. Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: results of treatment with intravesical bacillus Calmette-Guérin. J Urol 139 (1988) 290-293
23. Bretton P.R., Herr H.W., Whitmore Jr. W.F., et al. Intravesical bacillus Calmette-Guérin therapy for in situ transitional cell carcinoma involving the prostatic urethra. J Urol 141 (1989) 853-856
24. Sakamoto N., Tsuneyoshi M., Naito S., et al. An adequate sampling of the prostate to identify prostatic involvement by urothelial carcinoma in bladder cancer patients. J Urol 149 (1993) 318-321
25. Donat S.M., Genega E.M., Herr H.W., et al. Mechanisms of prostatic stromal invasion in patients with bladder cancer: clinical significance. J Urol 165 (2001) 1117-1120
26. Lamm R.L., Stodgill U.D., Stodgill B.J., et al. Complications of bacillus Calmett-Guérin immunotherapy in 1,278 patients with bladder cancer. J Urol 135 (1986) 272-274
27. Morales A., Eidinger D., and Bruce A.W. Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 116 (1976) 180-183
28. Herr H.W. Carcinoma in situ of the bladder. Semin Urol 1 (1983) 15-19
29. Lamm D.L. BCG immunotherapy in bladder cancer. J Urol 134 (1985) 40-47
30. de Kernion J.B., Hvany M.Y., Linanfr A., et al. The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guérin. J Urol 133 (1985) 598-601
31. Palou J., Xavier B., Laguna P., et al. In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guérin therapy without previous transurethral resection of the prostate. Urology 47 (1996) 482-484
32. Canda A.E., Tuzel E., Mungan M.U., et al. Conservative management of mucosal prostatic involvement in patients with superficial transitional cell carcinoma of the bladder. Eur Urol 45 (2004) 465-469 discussion 469-470
33. Solsona E., Iborra I., Ricós J.V., et al. The prostate involvement as prognostic factor in patients with superficial bladder cancer. J Urol 154 (1995) 1710-1713
34. Chibber P.J., McIntyre M.A., Hindmarsh J.R., et al. Transitional cell carcinoma involving the prostate. Br J Urol 53 (1981) 605-609
35. Oates R.D., Stilmant M.M., Freedlund M.C., et al. Granulomatous prostatitis following bacillus Calmette-Guérin immunotherapy of bladder cancer. J Urol 140 (1988) 751-754
36. Mukamel E., Konichezky M., Engelstein D., et al. Clinical and pathological findings in prostates following intravesical bacillus Calmette-Guérin instillations. J Urol 144 (1990) 1399-1400
37. LaFontaine P.D., Middleman B.R., Graham S.D., et al. Incidence of granulomatous prostatitis and acid-fast bacilli after intravesical BCG therapy. Urology 49 (1997) 363-366
38. Palou J., Salvador J., Parada R., et al. Carcinoma in situ of the prostatic urethra: the role of intravesical BCG. Urología Integrada Investigación 6 (2001) 165-170
39. Ovesen H., Poulsen A.L., and Steven K. Intravesical bacillus Calmette-Guérin with the Danish strain for treatment of carcinoma in situ of the bladder. Br J Urol 72 pt 2 (1993) 744-748
40. Schwalb D.M., Herr H.W., and Fair W.R. The management of clinically unconfirmed positive urine cytology. J Urol 150 (1993) 1751-1756
41. Pieras Ayala E., Palou J., Rodriguez-Villamil L., et al. Cytoscopic follow-up of initial G3T1 bladder tumors treated with BCG. [in Spanish]. Arch Esp Urol 54 (2001) 211-217
42. Schwalb D.M., Herr H.W., Sogani P.C., et al. Positive urine cytology following complete response to intravesical bacillus Calmette-Guérin therapy: pattern of recurrence. J Urol 152 (1994) 382-387
43. Pagano F., Bassi P.F., Ferranti G.L., et al. Is stage pT4a (D1) reliable for assessing transitional cell carcinoma involvement of the prostate in patients with a concurrent bladder cancer?. A necessary distinction for contiguous or noncontiguous involvement. J Urol 155 (1996) 244-247
44. Coutts A.G., Grigor K.M., and Fowler J.W. Urethral dysplasia and bladder cancer in cystectomy specimens. Br J Urol 57 (1985) 535-541
45. Reese J.H., Freiha F.S., Gelb A.B., et al. Transitional cell carcinoma of the prostate in patients undergoing radical cystoprostatectomy. J Urol 147 (1992) 92-95
46. Njinou Ngninkeu B., Lorge F., Moulin P., et al. Transitional cell carcinoma involving the prostate: a clinicopathological retrospective study of 76 cases. J Urol 169 (2003) 149-152
47. Wood Jr. D.P., Montie J.E., Pontes J.E., et al. Identification of transitional cell carcinoma of the prostate in bladder cancer patients: a prospective study. J Urol 142 (1989) 83-85
48. Hardeman S.W., Perry A., and Soloway M.S. Transitional cell carcinoma of the prostate following intravesical therapy for transitional cell carcinoma of the bladder. J Urol 140 (1988) 289-292
49. Donat S.M., Wei D.C., McGuire M.S., et al. The efficacy of transurethral biopsy for predicting the long-term clinical impact of prostatic invasive bladder cancer. J Urol 165 (2001) 1580-1584
50. Vazina A., Dugi D., Shariat S.F., et al. Stage specific lymph node metastasis mapping in radical cystectomy specimens. J Urol 171 (2004) 1830-1834
51. Leissner J., Ghoneim M.A., Abol-Enein H., et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol 171 (2004) 139-144
52. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19 (2001) 666-675
53. Freeman J.A., Esring D., Stein J.P., et al. Management of the patient with bladder cancer: urethral recurrence. Urol Clin North Am 21 (1994) 645-651
54. Levinston A.K., Johnson D.E., and Wishnow K.I. Indications of urethrectomy in the era of continent urinary diversion. J Urol 144 (1990) 73-75
55. Hardeman S.W., and Soloway M.S. Urethral recurrence following radical cystectomy. J Urol 144 (1990) 666-669
56. Tongaonkar H.B., Dalal A.V., Kulkarni J.N., et al. Urethral recurrences following radical cystectomy for invasive transitional cell carcinoma of the bladder. Br J Urol 72 (1993) 910-914
57. Tobisu K., Kanai Y., Sakamoto M., et al. Involvement of the anterior urethra in male patients with transitional cell-carcinoma of the bladder undergoing radical cystectomy with simultaneous urethrectomy. Jpn J Clin Oncol 27 (1997) 406-409
58. Lebret T., Herve J.M., Barre P., et al. Urethral recurrence of transitional cell carcinoma of the bladder: predictive value of preoperative latero-montanal biopsies and urethral frozen sections during prostatocystectomy. Eur Urol 33 (1998) 170-174
59. Vallancien G., Abou El Fettouh H., Cathelineau X., et al. Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. J Urol 168 (2002) 2413-2417
60. Iselin C.E., Robertson C.N., Webster G.D., et al. Does prostate transitional cell carcinoma preclude orthotopic bladder reconstruction after radical cystoprostatectomy for bladder cancer?. J Urol 158 (1997) 2123
61. Bochner B.H., Herr H.W., and Reuter V.E. Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens. J Urol 166 (2001) 2295-2296
62. Jakse G., Algaba F., Fossa S., et al. European Association of Urology Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic. (2004), S Karger AG, Basel, Switzerland March
63. Freeman J.A., Tarter T.A., Esring D., et al. Urethral recurrence in patients with orthotopic ileal neobladders. J Urol 156 (1996) 1615-1619
64. Huguet J., Palou J., Serrallach M., et al. Management of urethral recurrence in patients with Studer ileal neobladder. Eur Urol 43 (2003) 495-498
65. Bulbul M.A., Wazzan W., Nasr R., et al. The value of cystoscopy, prostate biopsy and frozen-section urethral biopsy prior to orthotopic neobladder substitution. Can J Urol 8 (2001) 1290-1292